Background
SACC is the most common tumor in the minor salivary glands and the second most common tumor in the major salivary glands [
1,
2]. Dockerty and Mayo determined that SACC exhibited aggressive features [
3]. The disease is characterized by distant metastasis, a high-risk of relapse and a propensity for invading peripheral nerves. Most patients with SACC die within 5 to 20 years of diagnosis [
4]. Regional lymph node metastasis was deemed clinically undetectable in affected patients, while hematogenous metastasis to the lungs, bone and liver was frequently reported in patients [
5].
NOTCH signaling pathway is a traditional and complex signal pathway, which relates to tissue differentiation and proliferation. There are four NOTCH receptors and five ligands to interactive with each other in mammal. The relationship between disordered NOTCH1 and tumor development has been hotly debated. A volume of reports have demonstrated the role of NOTCH1 acting as oncogene but also tumor suppressor genetically in different cancers. Yuan and colleagues [
6] reported that breast cancer patients with NOTCH1 overexpression suffered a low recurrence free survival rate; Arcaroli et al. [
7] found that a NOTCH1 gene copy number gain was a worse prognostic in colorectal cancer. On the other hand, several studies reported that high NOTCH1 and NOTCH2 expression with early tumor stages might indicate a tumor-suppressive role of NOTCH signaling in gastric cancer [
8]. Intriguingly, hepatocellular carcinoma [
9] and medulloblastoma [
10] have been observed with both functions even in the same tumor type.
NOTCH is a classical pathway that could activate HES1. Wang et al. [
11] found that the expression of NOTCH1 and HES1 was up-regulated consistently in rectal neuroendocrine tumors and pancreatic neuroendocrine tumors. It means that there was a close relationship between NOTCH signaling pathway and HES gene family. HES1 is one of seven members of the HES gene family (HES1–7) [
12‐
14]. HES1 expression is induced by the NICD and encodes a nuclear protein belonging to the hairy and enhancer of related (HESR) family of basic helix-loop-helix (bHLH)-type transcriptional repressors [
15‐
20]. HES1 participates in cellular differentiation, cell apoptosis and cell self-renewal, and the expression level of HES1 is frequently abnormal in cancer cells. Mounting evidences support that HES1 is an oncogene in kinds of tumors. The absence of HES1 has been shown to weaken the tumorigenic capacity of oral squamous cell carcinoma cells [
21], as well as colon cancer [
22] and pancreatic cancer cells [
23].
Our previous study has convincingly verified that NOTCH1 contributed to the cell growth, anti-apoptosis and metastasis of SACC [
24]. However, as a complicated signaling pathway, we know little about the influence of this pathway’s upstream or downstream genes in human SACC. Aster’s animal study [
25] uncovered harmful side effects by systemic inhibition of NOTCH signaling. So it’s quite important to find the target genes of the pathway and provide a specific means to treat cancer. The objectives of the present study were to illuminate the effects of target gene of NOTCH signaling pathway in human SACC. We analyzed the changes of transcriptome in SACC cells exhibiting NOTCH1 up-regulation by RNA-Seq and verified that HES1 was a specific downstream target of NOTCH1 signaling. HES1 was employed for further study and we compared HES1 expression levels between clinical SACC samples and normal samples using immunohistochemical staining. We also silenced HES1 expression in SACC cell line to determine the effects of HES1 on SACC cell proliferation, migration and invasion and to elucidate the mechanism by which these cells undergo apoptosis.
Methods
Cell culture and clinical samples
The SACC cell lines SACC-LM and SACC-83 were obtained from the Peking University Health Science Center. The cells were maintained in RPMI-1640 (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco). The tissue samples were obtained from Fuzhou General Hospital of Nanjing Military Command and Fujian Medical University Union Hospital. Fifty normal salivary tissue samples and 60 SACC samples were used in the study, which were approved by the Institutional Review Board of Fujian Medical University (IRB No. 35000401–11-054). Written informed consent was obtained from each participant.
RNAi transfection
A negative control (NC) siRNA and two siRNAs against HES1 were synthesized (GenePharma, Shanghai, China). The sequences of these siRNAs are listed in Table
1. The SACC LM cells were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, California, USA), according to the manufacturer’s instructions.
Table 1
The sequences of the siRNAs used in the transfection experiments
siRNA-HES1–425 | 5’-GGAUGCUCUGAAGAAAGAUTT-3’ | 5’-AUCUUUCUUCAGAGCAUCCTT-3’ |
siRNA-HES1–670 | 5’-CCAACUGCAUGACCCAGAUTT-3’ | 5’-AUCUGGGUCAUGCAGUUGGTT-3’ |
NC | 5’-UUCUCCGAACGUGUCACGUTT-3’ | 5’-ACGUGACACGUUCGGAGAATT-3’ |
Quantitative real-time PCR analysis
Total RNA was extracted from the SACC LM cells and was reverse transcribed into cDNA. The cDNA was used to detect the expression of the genes of interest by qRT-PCR, which was performed with SYBR Premix Ex Taq (Takara). The primers used in this study are listed in Table
2. The data were analyzed according to the 2
-△△Ct method.
Table 2
The primers for real-time PCR and semi-quantitative RT-PCR used in this study
ACTB | NM 001101 | CCTGGCACCCAGCACAAT | GGGCCGGACTCGTCATACT |
HES1 | NM 005524.3 | AGGCGGACATTCTGGAAATG | CGGTACTTCCCCAGCACACTT |
NOTCH1 | NM 017617.3 | GGAAGTTGAACGAGCATAGTCC | GCATGATGCCTACATTTCAAGA |
CCND1 | NM 053056.2 | CCCCGCACGATTTCATTGAACA | CATGGAGGGCGGATTGGAAATG |
Ki67 | NM 002417.4 | GCTCCCCACCTCAGAGAGTTTT | CTCTTAAGGGAGGGCTTGCAGA |
KRT14 | NM 000526.4 | GAGCCGCATTCTGAACGAGATG | ACTGCAGCTCAATCTCCAGGTT |
IGFBP7 | NM 001553.2 | GATGCTGGAGAATATGAGTGCC | CCATGACTACTTTTAACCATGCA |
PSCA | NM 005672.4 | CCAGGTGAGCAACGAGGACT | TAGTCCTGTGAGTCATCCACGC |
S100A2 | NM 005978.3 | ATAAATCCTCACCCTGGGAGCC | CCCTCTTGGCAGGAGTACTTGT |
C9ORF3 | NM 032823.5 | TCTGCGGAAGTGGTGACCC | AGGGTCCAGCTGTATGTCCATG |
MMP9 | NM 004994.2 | GAGGCGCTCATGTACCCTATGT | GGTGTGGTGGTGGTTGGAGG |
RNA isolation, library construction and sequencing
Total RNA was extracted using a mirVana miRNA Isolation Kit (Ambion), according to the manufacturer’s protocol, and RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples with an RNA Integrity Number (RIN) ≥ 7 were subjected to subsequent analyses. The libraries were constructed using a TruSeq Stranded mRNA LTSample Prep Kit (Illumina, San Diego, California, USA), according to the manufacturer’s instructions. These libraries were then sequenced on an Illumina sequencing platform (HiSeqTM 2500) and 150 bp paired-end reads were generated. Raw data (raw reads) were processed using custom scripts, and ploy-N-containing reads, PCR duplications and low-quality reads were removed to obtain clean reads, which were then mapped to the hg19 genome, which served as a reference, using Tophat (
http://ccb.jhu.edu/software/tophat/index.shtml).
Immunohistochemistry
For the immunohistochemical assays, 5-μm-thick tissue sections were incubated with a primary antibody against HES1 (1:6400, CST, Boston, Massachusetts, USA). All the slides were reviewed independently by two pathologists who were blinded to the other’s readings. The immunohistochemical analysis results were graded with the indicated four-tier scoring system (negative, weakly positive, positive, and strongly positive).
Western blot assay
Total protein was separated by 8% SDS-PAGE and then transferred onto PVDF membranes (Amersham, Piscataway, NJ, USA), which were immunoblotted with primary antibodies against HES1 (1:1000 dilution, CST) and GAPDH (1:1000 dilution, CST) overnight and incubated with the appropriate secondary antibodies (1:2000 dilution, Abcam, London, UK). The immunoreactive protein bands were visualized using CDP STAR reagent (Roche, Basel, Switzerland).
Cell viability assay
Cell proliferation was measured by counting viable cells with Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan). The cells were first transfected with siRNAs for 24 h and then plated in a 96-well plate. At the same time during each of the following 5 days, the absorbance of each well was measured at 450 nm with a microplate reader (BioTek, Vermont, USA).
Twenty-four hours after siRNA transfection, the cells were plated in 6-cm plates (600 cells per plate) and cultured for 2 weeks. The colonies were stained with 1% crystal violet.
Wound healing assay
SACC LM cells were transfected with siRNAs for 24 h after being seeded in a 6-well plate. A 20-μl pipette tip was used to establish a scratch-wound model until the cells amplificated and formed a monolayer covering the bottom of the plate. Then the medium was replaced with 1640 supplemented with 0.1% FBS. The width of scratch-wound was visualized to evaluate the cell invasion ability under a light microscope at the time points of 0 and 72 h and the images were captured.
Cell invasion and migration assay
Cell invasion was assessed using 24-well Matrigel-coated transwell chambers (8-μm pore size, BD Science, Franklin Lakes, New Jersey, USA). 24 h after siRNA transfection, the cells were serum starved for 24 h and then suspended in 1640 containing 1% FBS. The cells were subsequently plated in the upper transwell chamber at a density of 1.0 × 105 cells/well, and 800 μl of 1640 containing 10% FBS was added to the lower transwell chamber. After incubating for 48 h at 37 °C, the cells in the lower chamber were stained and counted. Cell migration assays were performed with transwell not coated with Matrigel.
Cell apoptosis and cell cycle assay
Cellular apoptosis was analyzed using an FITC/Annexin V Apoptosis Detection Kit (BD Pharmingen). Cell cycle activity was analyzed using a Cycletest Plus DNA Reagent Kit (BD Pharmingen). The percentage of apoptotic cells and the distributions of the cells in each cell cycle phase were determined using a BD FACS Verse Flow Cytometer.
Xenograft cancer model
The experimental animal protocol was approved by the Animal Care and Use Committee of Fujian Medical University. Female BALB/c nude mice aged 6~ 8 weeks were purchased from the Center for Animal Experiments of Fujian Medical University. Nude mice were randomly assigned to three groups, each of which comprised 5 mice. The cells (2 × 106) were suspended in 0.2 ml of serum-free 1640 and then injected into the right axillary fossa of each mouse. Tumor size was measured three times a week and was calculated using the formula V = width2 × length/2. At the end of the experiment, the tumors were harvested, washed once in PBS, and then weighed.
Statistical analysis
Statistical analysis of HES1 immunoreactivity was performed using the rank-sum test, and statistical analysis of the PCR and in vitro cell migration/invasion assay results was performed by Student’s t-test. P < 0.05 was considered statistically significant, and n.s. was indicated in the figures when P > 0.05, * when P < 0.05, **when P < 0.01 and *** when P < 0.001.
Discussion
There are emerging studies regarding SACC molecular biology. The genetic markers differentially expressed between cancerous cells and normal cells are molecules related to cell proliferation [
27], growth factor receptors and ligands [
28,
29], cell cycle oncogenes [
30,
31], cell adhesion proteins [
32], and transcription factors [
33,
34]. However, HES1 has never been reported to play a role in SACC. HES1 encodes nuclear proteins to activate transcription repression in two ways [
13,
35]. One is to form a non-DNA binding complex by joining with other bHLH factors via the bHLH domain, and another is to cooperate with co-repressor transducin-like enhancer of split (TLE) to prevent itself from binding to the N box through its WRPW motif and forming complexes [
36,
37]. HES1 induction may depend on several disease-specific and cell-dependent signaling pathways, such as the NOTCH pathway [
38], the hedgehog pathway [
39,
40], the c-Jun N-terminal kinase (JNK) signaling pathway [
41,
42] and the MAP kinase ERK pathway [
43]. These pathways appear to be involved in cross-talk with one another at the molecular level. NOTCH is a canonical pathway in the abovementioned pathways, and HES1 plays a prominent role in the NOTCH-HES1 axis. HES1 expression was activated upon the induction of the transcriptional complex CSL-NICD in the nucleus [
44]. The NOTCH signaling pathway has been reported to link various microenvironmental factors to the occurrence and development of malignant tumors. Following our previous study regarding the role of the NOTCH1 signaling pathway in SACC, we devoted our attention to systemically studying NOTCH1 [
24]. In this study, we revalidate HES1 as the definite downstream gene of NOTCH1 in SACC cells via RNA-Seq analysis. Immunochemistry showed that HES1 expression levels in SACC cancerous tissues were much higher than in those in para-cancerous tissues, too. All of these give us clues that HES1 is a valuable target gene of NOTCH1 signaling pathway and captivate us to carry out more research in SACC.
Cell proliferation is a recognized key contributor to the rapid development of cancer. And stem cells are the source of cancer cells endless proliferation. Many studies indicate that HES1 has the potential to induce cancer stem cells with self-transforming ability and to trigger apoptosis resistance and oncogenesis progression. In addition, the NOTCH-HES1 pathway was verified to affect stem cell maintenance in breast cancer [
45]. Our study found that the cells growth ability of SACC cells was affected by HES1. As for illuminating the relationship between HES1 and the stem cells of SACC, we will need an in-depth study in the future. It has also been reached to a consensus that HES1 is associated with apoptosis [
22]. Cancer cell differentiation and apoptosis can be stimulated via NOTCH and hedgehog pathway inhibition. It is suspected that differentiation is suppressed by HES1-mediated histone deacetylase (HDAC) inhibition. HDACs have been shown to induce differentiation or apoptosis in tumors and may thus be useful as anti-tumor therapeutic agents [
46]. HES1 downregulation induces growth arrest and apoptosis in acute myeloid leukemia (AML) cells; thus, HES1 may be a novel target for the treatment of AML [
47]. The execution-phase of cell apoptosis can be sequentially activated by CASP. CASP3 and CASP9 are common members of the CASP family and interact with each otherCASP9 can process and activate CASP3 [
48]. To explore the relationship between HES1 downregulation and apoptosis inducement in SACC cells, flow cytometry was involved in our research. It provided new insight that HES1 shared a close association with apoptosis by attracting our attention on apoptosis-related genes, such as CASP3 and CASP9, which might induce apoptosis in SACC cells.
The fate of invasion and metastasis is associated with epithelial-to-mesenchymal transition (EMT), as previous studies have shown that EMT is triggered in metastatic prostate cancer PC3 cells [
49]. Otherwise, Fei Gao [
22] demonstrated that EMT was enhanced by HES1, which facilitates colon cancer cell aggressiveness and inhibited by HES1 silencing. Weng MT found that HES1 controls invasiveness via the STAT3-MMP14 pathway in colorectal cancer (CRC) cells [
50]. Our research also implied that HES1 promoted SACC cells migration and invasion ability, and the clinical samples analysis indicated that the high expression of HES1 in SACC might relate to more metastasis.
It is noteworthy that, the cell or tissue samples and data mining we conducted in the study were insufficiency, so larger sample size would be attempted in the future. In the meanwhile, further studies are needed to clarify specific molecule mechanism of the proliferation and metastasis of HES1 in SACC.
Conclusions
We have determined that HES1 played a vital role in maintaining metastasis, proliferation and apoptosis in SACC cells; thus, targeting HES1 may represent a promising means by which SACC can be treated. In addition to playing a role in the NOTCH signaling pathway, treatments targeting HES1 may cause fewer side effects than those targeting whole NOTCH signaling pathway totally. Therefore, clinicians and researchers should devote significant attention to developing clinical therapies designed to target HES1.